EuroGuiDerm寻常型银屑病全身治疗指南-第1部分:治疗和监测建议

2021-02-03 欧洲皮肤病学论坛 J Eur Acad Dermatol Venereol . 2020 Nov;34(11):2461-2498

该基于证据和共识的寻常型银屑病治疗指南是根据《 EuroGuiDerm指南和共识声明开发手册》制定的。 指南的第一部分包括有关范围和目的,涵盖的健康问题,目标用户以及指南的强度/限制的一般信息。 提供

中文标题:

EuroGuiDerm寻常型银屑病全身治疗指南-第1部分:治疗和监测建议

发布机构:

欧洲皮肤病学论坛

发布日期:

2021-02-03

简要介绍:

该基于证据和共识的寻常型银屑病治疗指南是根据《 EuroGuiDerm指南和共识声明开发手册》制定的。 指南的第一部分包括有关范围和目的,涵盖的健康问题,目标用户以及指南的强度/限制的一般信息。 提供了有关疾病严重程度分级和治疗目标的建议。 它提供了一般治疗建议以及针对每种药物的详细管理和监测建议。 本指南中讨论的治疗选择如下:acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

第二部分见:EuroGuiDerm寻常型银屑病的全身治疗指南-第2部分:特定的临床和合并症

相关资料下载:
[AttachmentFileName(sort=1, fileName=jdv.16926.pdf)] GetToolGuiderByIdResponse(projectId=1, id=83a531c00205a1b7, title=EuroGuiDerm寻常型银屑病全身治疗指南-第1部分:治疗和监测建议 , enTitle=, guiderFrom=J Eur Acad Dermatol Venereol . 2020 Nov;34(11):2461-2498, authorId=0, author=, summary=该基于证据和共识的寻常型银屑病治疗指南是根据《 EuroGuiDerm指南和共识声明开发手册》制定的。 指南的第一部分包括有关范围和目的,涵盖的健康问题,目标用户以及指南的强度/限制的一般信息。 提供, cover=, journalId=0, articlesId=null, associationId=450, associationName=欧洲皮肤病学论坛, associationIntro=The practice of dermatology has, over the past 30 years, been distinguished by its transition from provision of essentially empirical treatments to a practice in which rational therapies, based on enhanced knowledge of the pathogenesis of disease, are administered. Coincidentally, the boundaries between organ specific specialities such as our own have become blurred. Thus there is now great overlap with numerous other medical disciplines. These include: oncology, immunology / allergology, plastic surgery, oral medicine and, increasingly rheumatology and other disciplines in which management of chronic inflammatory disease plays an important role., copyright=0, guiderPublishedTime=Wed Feb 03 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">该基于证据和共识的寻常型银屑病治疗指南是根据《 EuroGuiDerm指南和共识声明开发手册》制定的。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="1">指南的第一部分包括有关范围和目的,涵盖的健康问题,目标用户以及指南的强度/限制的一般信息。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="2">提供了有关疾病严重程度分级和治疗目标的建议。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="3">它提供了一般治疗建议以及针对每种药物的详细管理和监测建议。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="4">本指南中讨论的治疗选择如下:<span style="color: #212121;">acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.</span></span></p> <p>第二部分见:<a href="https://www.medsci.cn/guideline/show_article.do?id=cf9511c00205a047" target="_blank" rel="noopener">EuroGuiDerm寻常型银屑病的全身治疗指南-第2部分:特定的临床和合并症</a></p>, tagList=[TagDto(tagId=4418, tagName=银屑病)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤与性病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8330, appHits=179, showAppHits=0, pcHits=664, showPcHits=8149, likes=1, shares=15, comments=15, approvalStatus=1, publishedTime=Wed Feb 10 19:57:54 CST 2021, publishedTimeString=2021-02-03, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=fbzhang, createdTime=Wed Feb 10 19:57:40 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 08:17:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=jdv.16926.pdf)])
jdv.16926.pdf
下载请点击:
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1064152, encodeId=276f106415245, content=怎么翻译成中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210914/64ab02e7412e4bb9bd16761e5ec01d40/f4b009acb5ad48ebbc530cb9d15a3aaa.jpg, createdBy=a57f5584285, createdName=ms9000000575742753, createdTime=Tue Oct 26 17:58:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051856, encodeId=cbc91051856d7, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:32 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006743, encodeId=3a0c1006e43ba, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc5c5467719, createdName=医海拾贝, createdTime=Tue Aug 10 21:35:22 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004041, encodeId=9aed10040413b, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ef85166597, createdName=杨敏, createdTime=Fri Jul 30 22:04:37 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978761, encodeId=591f9e876198, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4515212333, createdName=14761874m39暂无昵称, createdTime=Thu Jul 01 20:50:51 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-10-26 ms9000000575742753

    怎么翻译成中文

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1064152, encodeId=276f106415245, content=怎么翻译成中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210914/64ab02e7412e4bb9bd16761e5ec01d40/f4b009acb5ad48ebbc530cb9d15a3aaa.jpg, createdBy=a57f5584285, createdName=ms9000000575742753, createdTime=Tue Oct 26 17:58:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051856, encodeId=cbc91051856d7, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:32 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006743, encodeId=3a0c1006e43ba, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc5c5467719, createdName=医海拾贝, createdTime=Tue Aug 10 21:35:22 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004041, encodeId=9aed10040413b, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ef85166597, createdName=杨敏, createdTime=Fri Jul 30 22:04:37 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978761, encodeId=591f9e876198, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4515212333, createdName=14761874m39暂无昵称, createdTime=Thu Jul 01 20:50:51 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-09-16 湘雅科教

    受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1064152, encodeId=276f106415245, content=怎么翻译成中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210914/64ab02e7412e4bb9bd16761e5ec01d40/f4b009acb5ad48ebbc530cb9d15a3aaa.jpg, createdBy=a57f5584285, createdName=ms9000000575742753, createdTime=Tue Oct 26 17:58:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051856, encodeId=cbc91051856d7, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:32 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006743, encodeId=3a0c1006e43ba, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc5c5467719, createdName=医海拾贝, createdTime=Tue Aug 10 21:35:22 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004041, encodeId=9aed10040413b, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ef85166597, createdName=杨敏, createdTime=Fri Jul 30 22:04:37 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978761, encodeId=591f9e876198, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4515212333, createdName=14761874m39暂无昵称, createdTime=Thu Jul 01 20:50:51 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-08-10 医海拾贝

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1064152, encodeId=276f106415245, content=怎么翻译成中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210914/64ab02e7412e4bb9bd16761e5ec01d40/f4b009acb5ad48ebbc530cb9d15a3aaa.jpg, createdBy=a57f5584285, createdName=ms9000000575742753, createdTime=Tue Oct 26 17:58:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051856, encodeId=cbc91051856d7, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:32 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006743, encodeId=3a0c1006e43ba, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc5c5467719, createdName=医海拾贝, createdTime=Tue Aug 10 21:35:22 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004041, encodeId=9aed10040413b, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ef85166597, createdName=杨敏, createdTime=Fri Jul 30 22:04:37 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978761, encodeId=591f9e876198, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4515212333, createdName=14761874m39暂无昵称, createdTime=Thu Jul 01 20:50:51 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-07-30 杨敏

    感谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1064152, encodeId=276f106415245, content=怎么翻译成中文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210914/64ab02e7412e4bb9bd16761e5ec01d40/f4b009acb5ad48ebbc530cb9d15a3aaa.jpg, createdBy=a57f5584285, createdName=ms9000000575742753, createdTime=Tue Oct 26 17:58:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051856, encodeId=cbc91051856d7, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:32 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006743, encodeId=3a0c1006e43ba, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc5c5467719, createdName=医海拾贝, createdTime=Tue Aug 10 21:35:22 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004041, encodeId=9aed10040413b, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ef85166597, createdName=杨敏, createdTime=Fri Jul 30 22:04:37 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978761, encodeId=591f9e876198, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4515212333, createdName=14761874m39暂无昵称, createdTime=Thu Jul 01 20:50:51 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
    2021-07-01 14761874m39暂无昵称

    感谢分享

    0